11482 Federal Register / Vol. 76, No. 41 / Wednesday, March 2, 2011 / Notices 

General description of report: This 

information collection is mandatory (12 

U.S.C. 1844(c)). Confidential treatment 

is not routinely given to the data in 

these reports. However, confidential 

treatment for the reporting information, 

in whole or in part, can be requested in 

accordance with the instructions to the 

form, pursuant to sections (b)(4), (b)(6), 

and (b)(8) of the Freedom of Information 

Act [5 U.S.C. 522(b)(4)]. 

Abstract: The FR Y–11S is an 

abbreviated reporting form that collects 

four data items: Net income, total assets, 

equity capital, and total off-balancesheet data items. The FR Y–11S is filed 

annually, as of December 31, by top-tier 

BHCs for each individual nonbank 

subsidiary (that does not meet the 

criteria for filing the detailed report) 

with total assets of at least $50 million, 

but less than $250 million, or with total 

assets greater than 1 percent of the total 

consolidated assets of the top-tier 

organization. 

Current actions: On November 3, 

2010, the Federal Reserve published a 

notice in the Federal Register (75 FR 

67721) requesting public comment for 

60 days on the extension, without 

revision, of the Abbreviated Financial 

Statements of U.S. Nonbank 

Subsidiaries of U.S. Bank Holding 

Companies. The comment period 

expired on January 3, 2011. The Federal 

Reserve did not receive any comment 

letters. 

3. Report title: Abbreviated Financial 

Statements of Foreign Subsidiaries of 

U.S. Banking Organizations. 

Agency form number: FR 2314S. 

OMB control number: 7100–0073. 

Frequency: Annually. 

Reporters: U.S. state member banks, 

BHCs, and Edge or agreement 

corporations. 

Annual reporting hours: 787. 

Estimated average hours per response: 

1.0. 

Number of respondents: 787. 

General description of report: This 

information collection is mandatory (12 

U.S.C. 324, 602, 625, and 1844(c)). 

Confidential treatment is not routinely 

given to the data in these reports. 

However, confidential treatment for the 

reporting information, in whole or in 

part, can be requested in accordance 

with the instructions to the form, 

pursuant to sections (b)(4), (b)(6) and 

(b)(8) of the Freedom of Information Act 

[5 U.S.C. 522(b)(4), (b)(6) and (b)(8)]. 

Abstract: The FR 2314S is an 

abbreviated reporting form that collects 

four data items: Net income, total assets, 

equity capital, and total off-balancesheet data items. The FR 2314S is filed 

annually, as of December 31, for each 

individual subsidiary (that does not 

meet the criteria for filing the detailed 

report) with assets of at least $50 

million but less than $250 million, or 

with total assets greater than 1 percent 

of the total consolidated assets of the 

top-tier organization. 

Current actions: On November 3, 

2010, the Federal Reserve published a 

notice in the Federal Register (75 FR 

67721) requesting public comment for 

60 days on the extension, without 

revision, of the Abbreviated Financial 

Statements of Foreign Subsidiaries of 

U.S. Banking Organizations. The 

comment period expired on January 3, 

2011. The Federal Reserve did not 

receive any comment letters. 

4. Report title: Financial Reports of 

Foreign Banking Organizations. 

Agency form number: FR Y–7NS, FR 

Y–7Q. 

OMB control number: 7100–0125. 

Frequency: Annually and quarterly. 

Reporters: Foreign banking 

organizations. 

Annual reporting hours: FR Y–7NS: 

237; FR Y–7Q (quarterly): 340; FR Y–7Q 

(annual): 111. 

Estimated average hours per response: 

FR Y–7NS: 1.0; FR Y–7Q (quarterly): 

1.25; FR Y–7Q (annual): 1.0. 

Number of respondents: FR Y–7NS: 

237; FR Y–7Q (quarterly): 68; FR Y–7Q 

(annual): 111. 

General description of report: This 

information collection is mandatory (12 

U.S.C. 1844(c), 3106(c), and 3108). 

Confidential treatment is not routinely 

given to the data in these reports. 

However, confidential treatment for 

information, in whole or in part, on any 

of the reporting forms can be requested 

in accordance with the instructions to 

the form, pursuant to sections (b)(4) and 

(b)(6) of the Freedom of Information Act 

[5 U.S.C. 522(b)(4) and (b)(6)]. 

Abstract: The FR Y–7NS collect 

financial information for nonfunctionally regulated U.S. nonbank 

subsidiaries held by FBOs other than 

through a U.S. BHC, U.S. FHC, or U.S. 

bank. The FR Y–7NS is filed annually, 

as of December 31, by top-tier FBOs for 

each individual nonbank subsidiary 

(that does not meet the filing criteria for 

filing the detailed report) with total 

assets of at least $50 million, but less 

than $250 million. The FR Y–7Q 

collects consolidated regulatory capital 

information from all FBOs either 

quarterly or annually. FBOs that have 

effectively elected to become FHCs file 

the FR Y–7Q quarterly. All other FBOs 

(those that have not elected to become 

FHCs) file the FR Y–7Q annually. 

Current actions: On November 3, 

2010, the Federal Reserve published a 

notice in the Federal Register (75 FR 

67721) requesting public comment for 

60 days on the extension, without 

revision, of the Financial Reports of 

Foreign Banking Organizations. The 

comment period expired on January 3, 

2011. The Federal Reserve did not 

receive any comment letters. 

Board of Governors of the Federal Reserve 

System, February 24, 2011. 

Jennifer J. Johnson, 

Secretary of the Board. 

[FR Doc. 2011–4568 Filed 3–1–11; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Request for Comments on Human 

Subjects Protections in Scientific 

Studies 

AGENCY: The Presidential Commission 

for the Study of Bioethical Issues, Office 

of the Secretary, Department of Health 

and Human Services. 

ACTION: Notice. 

SUMMARY: The Presidential Commission 

for the Study of Bioethical Issues is 

requesting public comment on the 

Federal and international standards for 

protecting the health and well-being of 

participants in scientific studies 

supported by the Federal Government. 

DATES: To assure consideration, 

comments must be received by May 2, 

2011. 

ADDRESSES: Individuals, groups, and 

organizations interested in commenting 

on this topic may submit comments by 

e-mail to info@bioethics.gov or by mail 

to the following address: Public 

Commentary, The Presidential 

Commission for the Study of Bioethical 

Issues, 1425 New York Ave. NW., Suite 

C–100, Washington, DC 20005. 

FOR FURTHER INFORMATION CONTACT: 

Hillary Wicai Viers, Communications 

Director, The Presidential Commission 

for the Study of Bioethical Issues, 1425 

New York Avenue, NW., Suite C–100, 

Washington, DC 20005. Telephone: 

202–233–3963. E-mail: 

Hillary.Viers@bioethics.gov. Additional 

information may be obtained at http:// 

www.bioethics.gov. 

SUPPLEMENTARY INFORMATION: On 

November 24, 2009, the President 

established the Presidential Commission 

for the Study of Bioethical Issues 

(Commission) to advise him on 

bioethical issues generated by novel and 

emerging research in biomedicine and 

related areas of science and technology. 

The Commission is charged to identify 

and promote policies and practices that 

assure ethically responsible conduct of 

scientific research, healthcare delivery, 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 41 / Wednesday, March 2, 2011 / Notices 11483 

and technological innovation. In 

undertaking these duties, the 

Commission seeks to identify and 

examine specific bioethical, legal, and 

social issues related to potential 

scientific and technological advances; 

examine diverse perspectives and 

possibilities for international 

collaboration on these issues; and 

recommend legal, regulatory, or policy 

actions as appropriate. 

The Commission has begun a review 

of the current rules and standards for 

protecting human subjects in scientific 

studies supported by the Federal 

Government. The President requested 

this study on November 24, 2010, 

following revelations that the U.S. 

Public Health Service supported 

research on sexually transmitted 

diseases in Guatemala from 1946 to 

1948 involving the intentional infection 

of vulnerable populations. President 

Obama asked the Commission Chair ‘‘to 

convene a panel to conduct * * * a 

thorough review of human subjects 

protection to determine if Federal 

regulations and international standards 

adequately guard the health and wellbeing of participants in scientific 

studies supported by the Federal 

Government.’’ 

The President charged the 

Commission to seek the insights and 

perspective of international experts and 

consult with counterparts in the global 

community. The Commission will 

provide the President with a report of its 

findings and recommendations later this 

year. 

To implement this mission, the 

Commission wishes to develop a 

thorough understanding of the current 

U.S. and international standards for 

protecting the health and well-being of 

participants in scientific studies 

supported by the Federal Government. 

To this end, the Commission is inviting 

interested parties to provide input and 

advice through written comments. 

Among other issues, the Commission is 

interested in receiving comments on the 

existing standards for protecting human 

subjects, both domestically and 

internationally; how the current system 

of global research works in practice; and 

the ethical and social justice issues that 

emerge from the current research 

system. Comments concerning the 

benefits of medical research; differences 

across global norms and standards; 

standards for ancillary care and posttrial access to treatment; trial design; 

duties to participants; challenges, if any, 

faced by U.S.-funded researchers 

working internationally, or international 

researchers collaborating on U.S.- 

funded research; and other specific 

information are all especially welcome. 

The Commission is under a very tight 

deadline and would appreciate 

comments within 60 days. 

Please address comments by e-mail to 

info@bioethics.gov, or by mail to the 

following address: Public Commentary, 

The Presidential Commission for the 

Study of Bioethical Issues, 1425 New 

York Ave. NW., Suite C–100, 

Washington, DC 20005. Comments will 

be publicly available, including any 

personally identifiable or confidential 

business information that they contain. 

Trade secrets should not be submitted. 

Dated: February 17, 2011. 

Valerie H. Bonham, 

Executive Director, The Presidential 

Commission for the Study of Bioethical Issues. 

[FR Doc. 2011–4658 Filed 3–1–11; 8:45 am] 

BILLING CODE 4154–06–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Subcommittee on Procedures Review, 

Advisory Board on Radiation and 

Worker Health (ABRWH), National 

Institute for Occupational Safety and 

Health (NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting for the 

aforementioned subcommittee: 

Time and Date: 9 a.m.–5 p.m., March 

22, 2011. 

Place: Cincinnati Airport Marriott, 

2395 Progress Drive, Hebron, KY 41018. 

Telephone (859) 334–4611, Fax (859) 

334–4619. 

Status: Open to the public, but 

without a public comment period. To 

access by conference call dial the 

following information: (866) 659–0537, 

Participant Pass Code 9933701. 

Background: The ABRWH was 

established under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000 to advise the 

President on a variety of policy and 

technical functions required to 

implement and effectively manage the 

compensation program. Key functions of 

the ABRWH include providing advice 

on the development of probability of 

causation guidelines that have been 

promulgated by the Department of 

Health and Human Services (HHS) as a 

final rule; advice on methods of dose 

reconstruction which have also been 

promulgated by HHS as a final rule; 

advice on the scientific validity and 

quality of dose estimation and 

reconstruction efforts being performed 

for purposes of the compensation 

program; and advice on petitions to add 

classes of workers to the Special 

Exposure Cohort (SEC). 

In December 2000, the President 

delegated responsibility for funding, 

staffing, and operating the ABRWH to 

HHS, which subsequently delegated this 

authority to CDC. NIOSH implements 

this responsibility for CDC. The charter 

was issued on August 3, 2001, renewed 

at appropriate intervals, and will expire 

on August 3, 2011. 

Purpose: The ABRWH is charged with 

(a) Providing advice to the Secretary, 

HHS, on the development of guidelines 

under Executive Order 13179; (b) 

providing advice to the Secretary, HHS, 

on the scientific validity and quality of 

dose reconstruction efforts performed 

for this program; and (c) upon request 

by the Secretary, HHS, advising the 

Secretary on whether there is a class of 

employees at any Department of Energy 

facility who were exposed to radiation 

but for whom it is not feasible to 

estimate their radiation dose, and on 

whether there is a reasonable likelihood 

that such radiation doses may have 

endangered the health of members of 

this class. The Subcommittee on 

Procedures Review was established to 

aid the ABRWH in carrying out its duty 

to advise the Secretary, HHS, on dose 

reconstructions. The Subcommittee on 

Procedures Review is responsible for 

overseeing, tracking, and participating 

in the reviews of all procedures used in 

the dose reconstruction process by the 

NIOSH Division of Compensation 

Analysis and Support (DCAS) and its 

dose reconstruction contractor. 

Matters to be Discussed: The agenda 

for the Subcommittee meeting includes 

discussion of the following ORAU and 

OCAS procedures: ORAUT–RPRT–0044 

(‘‘Analysis of Bioassay Data with a 

Significant Fraction of Less-Than 

Results’’), OCAS TIB–0013 (‘‘Special 

External Dose Reconstruction 

Considerations for Mallinckrodt 

Workers’’), OTIB–014 (‘‘Rocky Flats 

Internal Dosimetry Co-Worker 

Extension’’), OTIB–019 (‘‘Analysis of 

Coworker Bioassay Data for Internal 

Dose Assignment’’), OTIB–0029 

(‘‘Internal Dosimetry Coworker Data for 

Y–12’’), OTIB–0047 (‘‘External Radiation 

Monitoring at the Y–12 Facility During 

the 1948–1949 Period’’), OTIB–0049 

(‘‘Estimating Doses for Plutonium 

Strongly Retained in the Lung’’), OTIB– 

0052 (‘‘Parameters to Consider When 

Processing Claims for Construction 

Trade Workers’’), OTIB–0054 (‘‘Fission 

and Activation Product Assignment for 

Internal Dose-Related Gross Beta and 

Gross Gamma Analyses’’), and OTIB– 


emcdonald on DSK2BSOYB1PROD with NOTICES